Is there a best TKI for chronic phase CML?

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• The last two decades have seen significant advancements in BCR/ABL1 tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).
• Five oral, effective, and generally well-tolerated TKIs are now available for CML management.
• Indefinite TKI therapy is common, necessitating careful consideration of long-term safety and patient quality of life.

Purpose of the Study:

• To guide clinicians in selecting the optimal BCR/ABL1 tyrosine kinase inhibitor (TKI) for individual patients with chronic myeloid leukemia (CML).
• To ensure the best duration and quality of life while minimizing treatment complications and costs.
• To provide evidence-based recommendations for TKI use, considering efficacy, toxicity, prognostic milestones, and molecular monitoring.

Main Methods:

• Review of clinical trial data and real-world evidence on the efficacy and safety of available TKIs for CML.
• Analysis of early and late toxicities associated with different TKI treatment options.
• Evaluation of prognostic significance of achieving molecular treatment milestones.
• Consideration of patient-specific factors including risk status, age, and comorbidities.

Main Results:

• Multiple TKIs offer high efficacy in treating all stages of Ph+ CML.
• Each TKI possesses a distinct profile of benefits, risks, and long-term safety considerations.
• Achieving molecular monitoring milestones is critical for assessing treatment response and prognosis.

Conclusions:

• Treatment selection for CML requires a comprehensive approach beyond just efficacy.
• Individualized TKI choice should integrate drug-specific benefits and risks with patient characteristics.
• Optimal TKI selection aims to maximize treatment duration, quality of life, and potential for cure while managing costs and toxicities.